Skip to content


Poteligeo (mogamulizumab) is an antibody pharmaceutical. Mogamulizumab was first approved as Poteligeo on 2018-08-08. It is used to treat mycosis fungoides and sezary syndrome in the USA. It has been approved in Europe to treat mycosis fungoides and sezary syndrome. The pharmaceutical is active against C-C chemokine receptor type 4.
Trade Name Poteligeo
Common Name Mogamulizumab
Indication mycosis fungoides, sezary syndrome
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now